GlassScriptPhysician profile
Joshua K Hu
NPI 1942494703
$4,528.84
in general payments reported to CMS, 2019-2025
26 companies · $566 in 2025
The $566 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $544 · 2020: $156 · 2021: $509 · 2022: $719 · 2023: $817 · 2024: $1,217 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,550 · Honoraria: $51.18.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,549.94 |
| Honoraria | $51.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,055.85 | 2022-2025 | |
| Biotissue Holdings INC. | $685.95 | 2022-2025 | |
| Johnson & Johnson Surgical Vision, INC. | $533.72 | 2019-2023 | Tecnis Iol, Tecnis Iol, One Series Ultra |
| Allergan, INC. | $389.38 | 2019-2022 | |
| Alcon Vision LLC | $269.15 | 2019-2025 | Tryptyr, Rocklatan, Clareon |
| Rxsight INC | $260.88 | 2021-2025 | Rxsight Contact Lens, Rxsight Injector Cartridge, Rxsight Light Delivery Device (Ldd) |
| Oyster Point Pharma, INC. | $182.21 | 2022-2025 | Tyrvaya, Ryzumvi |
| Sun Pharmaceutical Industries INC. | $142.37 | 2019-2024 | Cequa |
| Bausch & Lomb Americas INC. | $140.71 | 2023-2024 | Vyzulta, Miebo, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $133.83 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $130.04 | 2024-2025 | Xdemvy |
| Amgen INC. | $103.18 | 2024-2025 | Tepezza |
| Harrow Eye, LLC | $94.05 | 2024-2025 | Vevye |
| Horizon Therapeutics Plc | $89.31 | 2019-2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $79.09 | 2019-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ocular Therapeutix, INC. | $53.11 | 2021 | |
| Sight Sciences, INC. | $35.51 | 2021-2024 | Omni Surgical System |
| Rayner Intraocular Lenses Limited | $22.90 | 2023 | Rayone Spheric, Rayone Emv, Rayone Aspheric |
| Omeros Corporation | $19.74 | 2019 | |
| Shire North American Group INC | $18.85 | 2019 | |
| Mallinckrodt Hospital Products INC. | $18.84 | 2022 | |
| Thea Pharma INC. | $17.45 | 2024 | Iyuzeh |
| Dompe US, INC. | $16.16 | 2025 | Oxervate |
| Eyevance Pharmaceuticals LLC | $12.82 | 2021 | |
| Kala Pharmaceuticals, INC. | $12.50 | 2021 | |
| Quidel Corporation | $11.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joshua Hu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.